|
US$149.00 · In stock
Delivery: <= 3 days. True-PDF full-copy in English will be manually translated and delivered via email.
WS 196-2017: Classification of tuberculosi
Status: Valid WS 196: Evolution and historical versions
| Standard ID | Contents [version] | USD | STEP2 | [PDF] delivered in | Standard Title (Description) | Status | PDF |
| WS 196-2017 | English | 149 |
Add to Cart
|
3 days [Need to translate]
|
Classification of tuberculosi
| Valid |
WS 196-2017
|
| WS/T 196-2017 | English | RFQ |
ASK
|
3 days [Need to translate]
|
(Tuberculosis classification)
| |
WS/T 196-2017
|
| WS 196-2001 | English | 159 |
Add to Cart
|
2 days [Need to translate]
|
Classification of tuberculosis
| Obsolete |
WS 196-2001
|
PDF similar to WS 196-2017
Standard similar to WS 196-2017 GBZ 57 GB/T 31989 WS/T 381 WS/T 192 Basic data | Standard ID | WS 196-2017 (WS196-2017) | | Description (Translated English) | Classification of tuberculosi | | Sector / Industry | Health Industry Standard | | Classification of Chinese Standard | C61 | | Word Count Estimation | 6,646 | | Date of Issue | 2017-11-09 | | Date of Implementation | 2018-05-01 | | Older Standard (superseded by this standard) | WS 196-2001 | | Regulation (derived from) | State-Health-Communication (2017) 25 | | Issuing agency(ies) | National Health and Family Planning Commission of the People's Republic of China | WS 196-2017: Classification of tuberculosi---This is a DRAFT version for illustration, not a final translation. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.) will be manually/carefully translated upon your order.
(Tuberculosis classification)
ICS 11.020
C 59
ws
People's Republic of China health industry standards
Replacing WS 196-2001
Tuberculosis classification
Classification of tuberculosis
2017 - 11 - 09 Posted
2018 - 05 - 01 implementation
People's Republic of China National Health and Family Planning Commission released
Foreword
Chapter 3 of this standard is mandatory, the rest are recommended terms.
This standard was drafted in accordance with the rules given in GB/T 1.1-2009.
This standard replaces WS 196-2001 "Tuberculosis classification."
This standard compared with WS 196-2001, the main technical changes are as follows.
- An increase in latent infection with M. tuberculosis, inactive tuberculosis classification (see 3.1, 3.3);
- Include tracheal tuberculosis, bronchial tuberculosis and tuberculous pleurisy in the classification and management of tuberculosis (see 3.2.2.1).
This standard was drafted. China Center for Disease Control and Prevention, Beijing Chest Hospital Affiliated to Capital Medical University, the PLA third hospital,
Capital Medical University Affiliated Beijing Children's Hospital.
The main drafters of this standard. Wang Lixia, into poetry, Zhou Lin, Li Liang, Zhao Shunying, Zhou Xinhua, Tude Hua, Julia Ching, Lin Minggui,
Liu Ergyong, Lai Yu-based.
This standard replaces the standards previously issued as follows.
- WS 196-2001.
Tuberculosis classification
1 Scope
This standard specifies the classification of tuberculosis, inspection methods and medical record format.
This standard applies to all levels of medical and health institutions at all levels of TB classification.
2 Normative references
The following documents for the application of this document is essential. For dated references, only the dated versions apply
Pieces. For undated references, the latest edition (including all amendments) applies to this document.
WS 288 Diagnosis of tuberculosis
3 tuberculosis classification
3.1 Mycobacterium latent infection
Infection with Mycobacterium tuberculosis in the body, but no clinical TB, no clinical bacteriological or radiological TB
evidence.
3.2 active tuberculosis
3.2.1 Overview
With tuberculosis-related clinical symptoms and signs, Mycobacterium tuberculosis etiology, pathology, imaging and other tests with active tuberculosis
evidence. Active tuberculosis in accordance with the lesion, etiological examination results, drug resistance, treatment history classification.
3.2.2 by the lesion
3.2.2.1 Pulmonary tuberculosis. refers to the tuberculosis occurs in the lungs, trachea, bronchus and pleura and other parts. Divided into the following five types.
a) Primary pulmonary tuberculosis. Including primary syndrome and thoracic lymph node tuberculosis (children also include caseous pneumonia and trachea, bronchial junction
nuclear);
b) Hematogenous disseminated tuberculosis. including acute, subacute and chronic hematogenous disseminated tuberculosis;
c) Secondary TB. Including invasive tuberculosis, tuberculous meningitis, caseous pneumonia, chronic fibrous hollow tuberculosis and ruptured lung;
d) trachea, bronchial tuberculosis. including the trachea, bronchial and submucosal tuberculosis;
e) Tuberculous pleurisy. Includes dry, exudative pleurisy and tuberculous empyema.
3.2.2.2 Extrapulmonary tuberculosis. refers to the occurrence of tuberculosis in organs and sites other than the lungs. Such as lymph nodes (except intrathoracic lymph nodes), bone, off
Section, genitourinary system, gastrointestinal system, central nervous system and other parts. Extrapulmonary tuberculosis is named after diseased organs and sites.
3.2.3 according to the etiology test results
The test results are as follows.
a) smear-positive tuberculosis. smear acid-fast staining positive;
b) smear-negative tuberculosis. smear acid-fast staining negative;
c) culture of positive tuberculosis. mycobacterium culture positive;
d) culture of negative tuberculosis. mycobacterial culture negative;
e) Molecular biology-positive tuberculosis. Mycobacterium tuberculosis nucleic acid test positive;
f) Phlegm-free tuberculosis. patients did not receive sputum antacids stained smear, sputum mycobacteria culture, molecular biology.
Pathogenic classification of pulmonary tuberculosis reference implementation.
3.2.4 according to drug resistance status
3.2.4.1 Non-drug-resistant tuberculosis. Mycobacterium tuberculosis infected with tuberculosis patients found no resistance to the anti-TB drugs used in the test in vitro;
3.2.4.2 Drug-resistant tuberculosis. Mycobacterium tuberculosis infected with tuberculosis was confirmed in vitro in the presence of one or more anti-tuberculosis drugs
Can grow. Drug-resistant tuberculosis is divided into the following types.
a) Single-drug resistant TB, which means that Mycobacterium tuberculosis is resistant to a first-line anti-tuberculosis drug;
b) Multi-drug resistant tuberculosis. Mycobacterium tuberculosis is resistant to more than one first-line anti-TB drug, but excludes isoniazid, rifampin
At the same time resistant;
c) Multidrug-resistant tuberculosis (MDR-TB). Mycobacterium tuberculosis is resistant to at least two or more drugs including isoniazid and rifampicin
The first-line anti-TB drug resistance;
d) XDR-TB. Mycobacterium tuberculosis In addition to the first-line anti-TB drugs isoniazid, rifampicin resistance at the same time,
Also resistant to at least one of the second-line anti-tuberculosis drugs, fluoroquinolones, and three injectables (eg,
Kanamycin, amikacin, etc.);
e) Rifampin-Resistant Tuberculosis. Mycobacterium tuberculosis is resistant to rifampin, irrespective of its resistance to other anti-TB drugs.
3.2.5 according to the history of treatment
3.2.5.1 Newly diagnosed tuberculosis. Newly diagnosed patients refer to one of the following conditions.
a) Patients who have never been treated for anti-TB drugs because of tuberculosis;
b) Patients undergoing standard chemotherapy regimen while under-treated;
c) Patients undergoing irregular chemotherapy for less than 1 month.
3.2.5.2 retreatment tuberculosis. Retreatment patients refer to one of the following conditions.
a) patients who have been treated for more than 1 month with anti-TB drugs due to unreasonable or irregular tuberculosis;
b) Patients with initial failure and relapse.
3.3 Inactive tuberculosis
3.3.1 Inactive tuberculosis
No active tuberculosis related clinical signs and symptoms, bacteriological negative, imaging examination of one or more of the following performance, side by side
Lung imaging changes caused by other causes can be diagnosed as inactive pulmonary tuberculosis.
a) Calcified lesions (solitary or multiple);
b) Striped lesions (sharp edges);
c) induration lesions;
d) purify the void;
e) Pleural thickening, adhesions or calcification.
3.3.2 Inactive extra-pulmonary tuberculosis
Non-active diagnosis of extra-pulmonary tuberculosis with reference to the implementation of inactive tuberculosis.
4 inspection methods
4.1 etiological examination
4.1.1 Specimens
Sputum, body fluids (blood, pleural effusion, ascites, cerebrospinal fluid, joint effusion, etc.), pus, lavage fluid and so on.
4.1.2 inspection methods
The inspection method is as follows.
a) smear acid-fast bacilli examination;
b) Mycobacterium tuberculosis culture, strain identification and drug sensitivity test;
c) Mycobacterium tuberculosis nucleic acid test.
4.1.3 check the results
Record the results as follows.
a) bacteriological examination results of M. tuberculosis. positive, negative, not done;
b) identification results of strains. Mycobacterium tuberculosis complex, non-tuberculous mycobacteria;
c) anti-TB drug sensitivity test results. sensitive, resistant;
d) Mycobacterium tuberculosis nucleic acid test. negative, positive.
4.2 other inspection
Tuberculosis test also includes pathology, serology, tubercle pure protein derivative (PPD) test (see WS 288 for details), γ-
Interferon release test and other methods.
5 medical record format
5.1 Mycobacterium tuberculosis latent infection
According to the diagnosis, inspection methods and results in order to write.
Tubercle pure protein derivative (PPD) test in accordance with the actual measurement of induration diameter (mm) × diameter (mm) records, and record blisters,
Double circle and other performance.
γ-Interferon release test recorded values.
Example 1. Mycobacterium tuberculosis latent infection, PPD test 5 mm × 12 mm, blisters.
5.2 Active tuberculosis
5.2.1 Tuberculosis
According to the type of pulmonary tuberculosis, lesions, bacteriological test results, anti-TB drug sensitivity test results, the history of treatment, etc. written.
Example 2. Acute hematogenous disseminated tuberculosis, lungs, Tu (Yin), Pei (not done), initial treatment.
Example 3. secondary pulmonary tuberculosis, upper left lung, Tu (Yang), culture (Yang), multidrug resistance (isoniazid resistance, rifampicin, streptomycin, etc.) retreatment.
5.2.2 Extrapulmonary tuberculosis
According to pulmonary tuberculosis lesions, bacteriological examination (marked specimens), anti-TB drug susceptibility test results, treatment history, etc. written.
Example 4. right hip tuberculosis, joint fluid coating (Yin), Pei (not done), initial treatment.
Example 5. Tuberculous meningitis, cerebrospinal fluid smear (Yang), Pei (Yang), sensitive, naive.
5.3 Inactive tuberculosis
According to the lesion, the imaging performance of writing order.
Example 6. Inactive tuberculosis, upper left lung, calcified lesion (solitary).
Tips & Frequently Asked Questions:Question 1: How long will the true-PDF of WS 196-2017_English be delivered?Answer: Upon your order, we will start to translate WS 196-2017_English as soon as possible, and keep you informed of the progress. The lead time is typically 1 ~ 3 working days. The lengthier the document the longer the lead time. Question 2: Can I share the purchased PDF of WS 196-2017_English with my colleagues?Answer: Yes. The purchased PDF of WS 196-2017_English will be deemed to be sold to your employer/organization who actually pays for it, including your colleagues and your employer's intranet. Question 3: Does the price include tax/VAT?Answer: Yes. Our tax invoice, downloaded/delivered in 9 seconds, includes all tax/VAT and complies with 100+ countries' tax regulations (tax exempted in 100+ countries) -- See Avoidance of Double Taxation Agreements (DTAs): List of DTAs signed between Singapore and 100+ countriesQuestion 4: Do you accept my currency other than USD?Answer: Yes. If you need your currency to be printed on the invoice, please write an email to [email protected]. In 2 working-hours, we will create a special link for you to pay in any currencies. Otherwise, follow the normal steps: Add to Cart -- Checkout -- Select your currency to pay. Question 5: Should I purchase the latest version WS 196-2017?Answer: Yes. Unless special scenarios such as technical constraints or academic study, you should always prioritize to purchase the latest version WS 196-2017 even if the enforcement date is in future. Complying with the latest version means that, by default, it also complies with all the earlier versions, technically.
|